Ability of Somatostatin Receptor Scintigraphy to Identify Patients with Gastric Carcinoids: A Prospective Study
Gastric carcinoids are of increasing clinical concern because they may develop in hypergastrinemic states, especially with the increased chronic use of potent acid suppressants that can cause hypergastrinemia. However, gastric carcinoids are difficult to diagnose. Somatostatin receptor scintigraphy...
Gespeichert in:
| Veröffentlicht in: | The Journal of nuclear medicine (1978) 2000-10, Vol.41 (10), p.1646-1656 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1656 |
|---|---|
| container_issue | 10 |
| container_start_page | 1646 |
| container_title | The Journal of nuclear medicine (1978) |
| container_volume | 41 |
| creator | Gibril, Fathia Reynolds, James C Lubensky, Irina A Roy, Praveen K Peghini, Paolo L Doppman, John L Jensen, Robert T |
| description | Gastric carcinoids are of increasing clinical concern because they may develop in hypergastrinemic states, especially with the increased chronic use of potent acid suppressants that can cause hypergastrinemia. However, gastric carcinoids are difficult to diagnose. Somatostatin receptor scintigraphy (SRS) has a high sensitivity and specificity for localizing carcinoids in other locations. The purpose of this study was to determine whether SRS could localize gastric carcinoids.
Two groups of patients with Zollinger-Ellison syndrome (ZES) with hypergastrinemia, each having a different increased risk of developing gastric carcinoids, were studied. One hundred sixty-two consecutive patients with ZES were studied prospectively, with 39 having multiple endocrine neoplasia, type 1 (MEN-1) (high increased risk), and 123 not having MEN-1 (low increased risk). Patients were admitted to the hospital initially and then yearly, undergoing SRS with SPECT, upper gastrointestinal endoscopy, and Jumbo Cup biopsies of any gastric abnormalities, as well as random biopsies of the gastric body. Tumor localization studies were also performed. Both the results of the routine SRS interpretation and the results of a masked review, with particular attention to the stomach of high risk MEN-1 patients, were correlated with the gastric biopsy results.
Gastric SRS localization was positive in 19 (12%) of 162 patients. Sixteen patients had a gastric carcinoid, and 12 of these patients had SRS localization. The sensitivity of SRS in localizing a gastric carcinoid was 75%, with a specificity of 95%. Positive and negative predictive values were 63% and 97%, respectively.
SRS is a noninvasive method that can identify patients with gastric carcinoids with a reasonable sensitivity and a high specificity. SRS should prove useful in the treatment of patients with hypergastrinemic states that have an increased incidence of gastric carcinoids. In patients with MEN-1, one must realize that localization in the upper abdomen on SRS may be caused by a gastric carcinoid and not a pancreatic endocrine tumor. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72342770</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72342770</sourcerecordid><originalsourceid>FETCH-LOGICAL-h295t-529df16d0b10c7ca4956596da5b0e2c509088a66ab3c41f8378b21e1a77d22643</originalsourceid><addsrcrecordid>eNpd0E1r3DAQBmBTWppN2r8QRAslF4NGtr5yW5Y2CQQSus3ZjGU51mJbriQ3-N_HTbY95DQz8MzLMO-yDfCC51wI-T7bUBCQc075SXYa44FSKpRSH7MTAFpIrctN5re1611aiG_J3g-YfEyY3Eh-WmOn5APZGzcm9xhw6haSPLlp7Dq3C7lf3dpG8uRSR64wpuAM2WFYF7xr4iXZkvvg42RNcn8s2ae5WT5lH1rso_18rGfZw4_vv3bX-e3d1c1ue5t3TPOUc6abFkRDa6BGGiw1F1yLBnlNLTOcaqoUCoF1YUpoVSFVzcACStkwJsriLPv2mjsF_3u2MVWDi8b2PY7Wz7GSrCiZlHSFX97Ag5_DuN5WMdCgqX5JOz-iuR5sU03BDRiW6t8fV_D1CDAa7NuAo3Hxv1MAQslVXbyqzj12Ty7YapxNbzH8zTyMQwkV0ApEKYpnjyGKJQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219190964</pqid></control><display><type>article</type><title>Ability of Somatostatin Receptor Scintigraphy to Identify Patients with Gastric Carcinoids: A Prospective Study</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Gibril, Fathia ; Reynolds, James C ; Lubensky, Irina A ; Roy, Praveen K ; Peghini, Paolo L ; Doppman, John L ; Jensen, Robert T</creator><creatorcontrib>Gibril, Fathia ; Reynolds, James C ; Lubensky, Irina A ; Roy, Praveen K ; Peghini, Paolo L ; Doppman, John L ; Jensen, Robert T</creatorcontrib><description>Gastric carcinoids are of increasing clinical concern because they may develop in hypergastrinemic states, especially with the increased chronic use of potent acid suppressants that can cause hypergastrinemia. However, gastric carcinoids are difficult to diagnose. Somatostatin receptor scintigraphy (SRS) has a high sensitivity and specificity for localizing carcinoids in other locations. The purpose of this study was to determine whether SRS could localize gastric carcinoids.
Two groups of patients with Zollinger-Ellison syndrome (ZES) with hypergastrinemia, each having a different increased risk of developing gastric carcinoids, were studied. One hundred sixty-two consecutive patients with ZES were studied prospectively, with 39 having multiple endocrine neoplasia, type 1 (MEN-1) (high increased risk), and 123 not having MEN-1 (low increased risk). Patients were admitted to the hospital initially and then yearly, undergoing SRS with SPECT, upper gastrointestinal endoscopy, and Jumbo Cup biopsies of any gastric abnormalities, as well as random biopsies of the gastric body. Tumor localization studies were also performed. Both the results of the routine SRS interpretation and the results of a masked review, with particular attention to the stomach of high risk MEN-1 patients, were correlated with the gastric biopsy results.
Gastric SRS localization was positive in 19 (12%) of 162 patients. Sixteen patients had a gastric carcinoid, and 12 of these patients had SRS localization. The sensitivity of SRS in localizing a gastric carcinoid was 75%, with a specificity of 95%. Positive and negative predictive values were 63% and 97%, respectively.
SRS is a noninvasive method that can identify patients with gastric carcinoids with a reasonable sensitivity and a high specificity. SRS should prove useful in the treatment of patients with hypergastrinemic states that have an increased incidence of gastric carcinoids. In patients with MEN-1, one must realize that localization in the upper abdomen on SRS may be caused by a gastric carcinoid and not a pancreatic endocrine tumor.</description><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><identifier>PMID: 11037994</identifier><identifier>CODEN: JNMEAQ</identifier><language>eng</language><publisher>Reston, VA: Soc Nuclear Med</publisher><subject>Biological and medical sciences ; Carcinoid Tumor - diagnostic imaging ; Carcinoid Tumor - metabolism ; Case-Control Studies ; Digestion. Liver. Biliary tract. Spleen. Pancreas ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Indium Radioisotopes ; Investigative techniques, diagnostic techniques (general aspects) ; Male ; Medical sciences ; Middle Aged ; Multiple Endocrine Neoplasia Type 1 - diagnostic imaging ; Octreotide - analogs & derivatives ; Pentetic Acid - analogs & derivatives ; Predictive Value of Tests ; Prospective Studies ; Radionuclide investigations ; Radiopharmaceuticals ; Receptors, Somatostatin - metabolism ; Sensitivity and Specificity ; Stomach Neoplasms - diagnostic imaging ; Stomach Neoplasms - metabolism ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Tomography, Emission-Computed, Single-Photon ; Tumors ; Zollinger-Ellison Syndrome - diagnostic imaging</subject><ispartof>The Journal of nuclear medicine (1978), 2000-10, Vol.41 (10), p.1646-1656</ispartof><rights>2001 INIST-CNRS</rights><rights>Copyright Society of Nuclear Medicine Oct 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=811687$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11037994$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gibril, Fathia</creatorcontrib><creatorcontrib>Reynolds, James C</creatorcontrib><creatorcontrib>Lubensky, Irina A</creatorcontrib><creatorcontrib>Roy, Praveen K</creatorcontrib><creatorcontrib>Peghini, Paolo L</creatorcontrib><creatorcontrib>Doppman, John L</creatorcontrib><creatorcontrib>Jensen, Robert T</creatorcontrib><title>Ability of Somatostatin Receptor Scintigraphy to Identify Patients with Gastric Carcinoids: A Prospective Study</title><title>The Journal of nuclear medicine (1978)</title><addtitle>J Nucl Med</addtitle><description>Gastric carcinoids are of increasing clinical concern because they may develop in hypergastrinemic states, especially with the increased chronic use of potent acid suppressants that can cause hypergastrinemia. However, gastric carcinoids are difficult to diagnose. Somatostatin receptor scintigraphy (SRS) has a high sensitivity and specificity for localizing carcinoids in other locations. The purpose of this study was to determine whether SRS could localize gastric carcinoids.
Two groups of patients with Zollinger-Ellison syndrome (ZES) with hypergastrinemia, each having a different increased risk of developing gastric carcinoids, were studied. One hundred sixty-two consecutive patients with ZES were studied prospectively, with 39 having multiple endocrine neoplasia, type 1 (MEN-1) (high increased risk), and 123 not having MEN-1 (low increased risk). Patients were admitted to the hospital initially and then yearly, undergoing SRS with SPECT, upper gastrointestinal endoscopy, and Jumbo Cup biopsies of any gastric abnormalities, as well as random biopsies of the gastric body. Tumor localization studies were also performed. Both the results of the routine SRS interpretation and the results of a masked review, with particular attention to the stomach of high risk MEN-1 patients, were correlated with the gastric biopsy results.
Gastric SRS localization was positive in 19 (12%) of 162 patients. Sixteen patients had a gastric carcinoid, and 12 of these patients had SRS localization. The sensitivity of SRS in localizing a gastric carcinoid was 75%, with a specificity of 95%. Positive and negative predictive values were 63% and 97%, respectively.
SRS is a noninvasive method that can identify patients with gastric carcinoids with a reasonable sensitivity and a high specificity. SRS should prove useful in the treatment of patients with hypergastrinemic states that have an increased incidence of gastric carcinoids. In patients with MEN-1, one must realize that localization in the upper abdomen on SRS may be caused by a gastric carcinoid and not a pancreatic endocrine tumor.</description><subject>Biological and medical sciences</subject><subject>Carcinoid Tumor - diagnostic imaging</subject><subject>Carcinoid Tumor - metabolism</subject><subject>Case-Control Studies</subject><subject>Digestion. Liver. Biliary tract. Spleen. Pancreas</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Indium Radioisotopes</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple Endocrine Neoplasia Type 1 - diagnostic imaging</subject><subject>Octreotide - analogs & derivatives</subject><subject>Pentetic Acid - analogs & derivatives</subject><subject>Predictive Value of Tests</subject><subject>Prospective Studies</subject><subject>Radionuclide investigations</subject><subject>Radiopharmaceuticals</subject><subject>Receptors, Somatostatin - metabolism</subject><subject>Sensitivity and Specificity</subject><subject>Stomach Neoplasms - diagnostic imaging</subject><subject>Stomach Neoplasms - metabolism</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Tomography, Emission-Computed, Single-Photon</subject><subject>Tumors</subject><subject>Zollinger-Ellison Syndrome - diagnostic imaging</subject><issn>0161-5505</issn><issn>1535-5667</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpd0E1r3DAQBmBTWppN2r8QRAslF4NGtr5yW5Y2CQQSus3ZjGU51mJbriQ3-N_HTbY95DQz8MzLMO-yDfCC51wI-T7bUBCQc075SXYa44FSKpRSH7MTAFpIrctN5re1611aiG_J3g-YfEyY3Eh-WmOn5APZGzcm9xhw6haSPLlp7Dq3C7lf3dpG8uRSR64wpuAM2WFYF7xr4iXZkvvg42RNcn8s2ae5WT5lH1rso_18rGfZw4_vv3bX-e3d1c1ue5t3TPOUc6abFkRDa6BGGiw1F1yLBnlNLTOcaqoUCoF1YUpoVSFVzcACStkwJsriLPv2mjsF_3u2MVWDi8b2PY7Wz7GSrCiZlHSFX97Ag5_DuN5WMdCgqX5JOz-iuR5sU03BDRiW6t8fV_D1CDAa7NuAo3Hxv1MAQslVXbyqzj12Ty7YapxNbzH8zTyMQwkV0ApEKYpnjyGKJQ</recordid><startdate>20001001</startdate><enddate>20001001</enddate><creator>Gibril, Fathia</creator><creator>Reynolds, James C</creator><creator>Lubensky, Irina A</creator><creator>Roy, Praveen K</creator><creator>Peghini, Paolo L</creator><creator>Doppman, John L</creator><creator>Jensen, Robert T</creator><general>Soc Nuclear Med</general><general>Society of Nuclear Medicine</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>4T-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20001001</creationdate><title>Ability of Somatostatin Receptor Scintigraphy to Identify Patients with Gastric Carcinoids: A Prospective Study</title><author>Gibril, Fathia ; Reynolds, James C ; Lubensky, Irina A ; Roy, Praveen K ; Peghini, Paolo L ; Doppman, John L ; Jensen, Robert T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h295t-529df16d0b10c7ca4956596da5b0e2c509088a66ab3c41f8378b21e1a77d22643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Biological and medical sciences</topic><topic>Carcinoid Tumor - diagnostic imaging</topic><topic>Carcinoid Tumor - metabolism</topic><topic>Case-Control Studies</topic><topic>Digestion. Liver. Biliary tract. Spleen. Pancreas</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Indium Radioisotopes</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple Endocrine Neoplasia Type 1 - diagnostic imaging</topic><topic>Octreotide - analogs & derivatives</topic><topic>Pentetic Acid - analogs & derivatives</topic><topic>Predictive Value of Tests</topic><topic>Prospective Studies</topic><topic>Radionuclide investigations</topic><topic>Radiopharmaceuticals</topic><topic>Receptors, Somatostatin - metabolism</topic><topic>Sensitivity and Specificity</topic><topic>Stomach Neoplasms - diagnostic imaging</topic><topic>Stomach Neoplasms - metabolism</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Tomography, Emission-Computed, Single-Photon</topic><topic>Tumors</topic><topic>Zollinger-Ellison Syndrome - diagnostic imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gibril, Fathia</creatorcontrib><creatorcontrib>Reynolds, James C</creatorcontrib><creatorcontrib>Lubensky, Irina A</creatorcontrib><creatorcontrib>Roy, Praveen K</creatorcontrib><creatorcontrib>Peghini, Paolo L</creatorcontrib><creatorcontrib>Doppman, John L</creatorcontrib><creatorcontrib>Jensen, Robert T</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of nuclear medicine (1978)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gibril, Fathia</au><au>Reynolds, James C</au><au>Lubensky, Irina A</au><au>Roy, Praveen K</au><au>Peghini, Paolo L</au><au>Doppman, John L</au><au>Jensen, Robert T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ability of Somatostatin Receptor Scintigraphy to Identify Patients with Gastric Carcinoids: A Prospective Study</atitle><jtitle>The Journal of nuclear medicine (1978)</jtitle><addtitle>J Nucl Med</addtitle><date>2000-10-01</date><risdate>2000</risdate><volume>41</volume><issue>10</issue><spage>1646</spage><epage>1656</epage><pages>1646-1656</pages><issn>0161-5505</issn><eissn>1535-5667</eissn><coden>JNMEAQ</coden><abstract>Gastric carcinoids are of increasing clinical concern because they may develop in hypergastrinemic states, especially with the increased chronic use of potent acid suppressants that can cause hypergastrinemia. However, gastric carcinoids are difficult to diagnose. Somatostatin receptor scintigraphy (SRS) has a high sensitivity and specificity for localizing carcinoids in other locations. The purpose of this study was to determine whether SRS could localize gastric carcinoids.
Two groups of patients with Zollinger-Ellison syndrome (ZES) with hypergastrinemia, each having a different increased risk of developing gastric carcinoids, were studied. One hundred sixty-two consecutive patients with ZES were studied prospectively, with 39 having multiple endocrine neoplasia, type 1 (MEN-1) (high increased risk), and 123 not having MEN-1 (low increased risk). Patients were admitted to the hospital initially and then yearly, undergoing SRS with SPECT, upper gastrointestinal endoscopy, and Jumbo Cup biopsies of any gastric abnormalities, as well as random biopsies of the gastric body. Tumor localization studies were also performed. Both the results of the routine SRS interpretation and the results of a masked review, with particular attention to the stomach of high risk MEN-1 patients, were correlated with the gastric biopsy results.
Gastric SRS localization was positive in 19 (12%) of 162 patients. Sixteen patients had a gastric carcinoid, and 12 of these patients had SRS localization. The sensitivity of SRS in localizing a gastric carcinoid was 75%, with a specificity of 95%. Positive and negative predictive values were 63% and 97%, respectively.
SRS is a noninvasive method that can identify patients with gastric carcinoids with a reasonable sensitivity and a high specificity. SRS should prove useful in the treatment of patients with hypergastrinemic states that have an increased incidence of gastric carcinoids. In patients with MEN-1, one must realize that localization in the upper abdomen on SRS may be caused by a gastric carcinoid and not a pancreatic endocrine tumor.</abstract><cop>Reston, VA</cop><pub>Soc Nuclear Med</pub><pmid>11037994</pmid><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0161-5505 |
| ispartof | The Journal of nuclear medicine (1978), 2000-10, Vol.41 (10), p.1646-1656 |
| issn | 0161-5505 1535-5667 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72342770 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Biological and medical sciences Carcinoid Tumor - diagnostic imaging Carcinoid Tumor - metabolism Case-Control Studies Digestion. Liver. Biliary tract. Spleen. Pancreas Female Gastroenterology. Liver. Pancreas. Abdomen Humans Indium Radioisotopes Investigative techniques, diagnostic techniques (general aspects) Male Medical sciences Middle Aged Multiple Endocrine Neoplasia Type 1 - diagnostic imaging Octreotide - analogs & derivatives Pentetic Acid - analogs & derivatives Predictive Value of Tests Prospective Studies Radionuclide investigations Radiopharmaceuticals Receptors, Somatostatin - metabolism Sensitivity and Specificity Stomach Neoplasms - diagnostic imaging Stomach Neoplasms - metabolism Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Tomography, Emission-Computed, Single-Photon Tumors Zollinger-Ellison Syndrome - diagnostic imaging |
| title | Ability of Somatostatin Receptor Scintigraphy to Identify Patients with Gastric Carcinoids: A Prospective Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T12%3A40%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ability%20of%20Somatostatin%20Receptor%20Scintigraphy%20to%20Identify%20Patients%20with%20Gastric%20Carcinoids:%20A%20Prospective%20Study&rft.jtitle=The%20Journal%20of%20nuclear%20medicine%20(1978)&rft.au=Gibril,%20Fathia&rft.date=2000-10-01&rft.volume=41&rft.issue=10&rft.spage=1646&rft.epage=1656&rft.pages=1646-1656&rft.issn=0161-5505&rft.eissn=1535-5667&rft.coden=JNMEAQ&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E72342770%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219190964&rft_id=info:pmid/11037994&rfr_iscdi=true |